Introduction
Clostridium difficile (C. difficile) causes pseudomembranous colitis in humans and animals [3, 9, 21] by releasing two bacterial toxins: toxin A and toxin B [14, 22] . These toxins trigger cytoskeletal disorganization and apoptosis of the gut epithelial cells that are responsible for mucosal barrier function [6, 22] , leading to a severe inflammatory reaction [6, 18] . Many antibiotics, including vancomycin and metronidazole, have been used to effectively treat the disease symptoms [16] , but there have been problems with drug-resistant C. difficile [23] . Thus, we need to develop new non-antibiotic therapies.
C. difficile toxins have been shown to prevent Rho family proteins (e.g., Rho, Rac, and cdc42) from participating in the formation of actin filaments [8] . This mechanism is believed to be a main cause for the cell rounding that is characteristic of toxin-exposed cells [6, 18] . However, we recently reported that the toxin A-induced cytoskeletal disorganization of colonocytes was highly enhanced by the microtubule disassembly resulted from tubulin deacetylation [18] . In the same work, we further showed that toxin A activated histone deacetylase 6 (HDAC-6), which deacetylates tubulin proteins and thereby governs microtubule disassembly.
Microtubules are composed of α-tubulin and β-tubulin, and are regulated by post-translational modifications such as tyrosination and acetylation [19, 20] . Acetylation of α-tubulin at Lys-40 (K40) has been reported to enhance microtubule polymerization [28] , whereas HDAC-6 has been implicated in the deacetylation of α-tubulin [7, 18, 28] . Clostridium difficile toxin A is known to cause deacetylation of tubulin proteins, which blocks microtubule formation and triggers barrier dysfunction in the gut. Based on our previous finding that the Clostridium difficile toxin A-dependent activation of histone deacetylase 6 (HDAC-6) is responsible for tubulin deacetylation and subsequent microtubule disassembly, we herein examined the possible effect of potassium acetate (PA; whose acetyl group prevents the binding of tubulin to HDAC-6) as a competitive/false substrate. Our results revealed that PA inhibited toxin A-induced deacetylation of tubulin and recovered toxin A-induced microtubule disassembly. In addition, PA treatment significantly decreased the production of IL-6 (a marker of inflamed tissue) in the toxin A-induced mouse enteritis model. An in vitro HDAC assay revealed that PA directly inhibited HDAC-6-mediated tubulin deacetylation, indicating that PA acted as a false substrate for HDAC-6. These results collectively indicate that PA treatment inhibits HDAC-6, thereby reducing the cytotoxicity and inflammatory responses caused by C. difficile toxin A.
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Indeed, we previously showed that treatment with trichostatin A (TSA), a chemical inhibitor of HDAC-6, significantly reduced the cytoskeletal disorganization in colonic epithelial cells and inhibited the severe gut inflammation seen in the toxin A-treated mouse model of enteritis [18] . These results suggest that HDAC-6 could be a critical target for inhibiting the toxins produced by C. difficile.
Potassium acetate (PA) has been used to remove proteins during the isolations of DNA and RNA [2, 15, 24, 25] , for fixation of animal tissues in biological studies, as a food preservative [13] , and to treat diabetic ketoacidosis via its ability to break down into bicarbonate [27] . Moreover, PA can help neutralize the human body from an acidotic state [27] . However, no previous study has examined the possible effect of PA as a therapeutic agent for the treatment of gut inflammation.
Here, we report that PA directly inhibits the enzymatic activity of HDAC-6, rescues the α-tubulin deacetylation seen in toxin A-treated cells, and reduces the signs of cellular toxicity (e.g., cell rounding in vitro and gut inflammation in vivo) caused by C. difficile toxin A. Collectively, these results suggest that PA specifically inhibits HDAC-6 in colonocytes, and could be a candidate drug for the treatment of toxin A-induced gut inflammation.
Materials and Methods

Toxin A Preparation and Cell Culture
Toxin A was purified from C. difficile strain 10463 (American Type Culture Collection, Rockville, MD, USA) as previously described [12] . The purity of the native toxin A was assessed by gel electrophoresis, which confirmed a single protein band at the expected molecular mass of 307 kDa [26] . HT29 human colorectal adenocarcinoma cells were cultured in McCoy's 5A medium (Invitrogen, Carlsbad, CA, USA) in a 37°C humidified incubator supplemented with 5% CO 2 .
Antibodies and Reagents
Polyclonal antibodies against α-tubulin, acetylated α-tubulin, acetylated histone H3, HSP90, c-Src, and HDAC-6 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). PA, TSA, and the antibody against β-actin were purchased from Sigma Aldrich (St. Louis, MO, USA). The polyclonal antibody against caspase-3 was obtained from Cell Signaling Technology (Beverly, MA, USA).
Immunoblot Analysis
HT29 cells were washed with cold phosphate-buffered saline (PBS) and lysed in a buffer containing 150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 5 mM EDTA, and 1% Nonidet P-40 [17] . Equal amounts of protein were fractionated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). The appropriate antibodies were applied, and antigen-antibody complexes were detected with the LumiGlo reagent (New England Biolabs, Ipswich, MA, USA).
Enzymatic Activity Assay for HDAC-6 HDAC-6 activity was measured as the absence or presence of PA, which was assessed using immunoprecipitation with an antibody against HDAC-6 and visualized using a fluorescence activity assay kit (Cayman Chemical, Ann Arbor, MI, USA), as previously described [18] . Briefly, each extract (1 µg) or immunoprecipitant was incubated at 37°C with 100 µM acetylated fluorogenic substrate in HDAC assay buffer. After 30 min, the lysine developer was added, and the mixture was incubated for another 15 min at room temperature. Fluorescence was measured using a Spectra Max M5 fluorescent plate reader (Molecular Devices, Sunnyvale, CA, USA) with excitation at 360 nm and emission at 460 nm.
Animals
This study was approved by the Animal Care and Use Committee of Daejin University (Pocheon, Korea). Male CD1 mice (Daehan Biolink, Daejeon, Korea) weighing 30-35 g were used; they had free access to food and water and were acclimated to these conditions for at least 7 days prior to experiments [10] . Mice were anesthetized by intraperitoneal injection of sodium pentobarbital (50 mg/kg). Ileal loops (2 cm) were prepared and injected with control buffer (PBS), PA (10 µM), toxin A (3 nM), or toxin A plus PA in a volume of 100 µl of PBS. After 4 h, animals were sacrificed and ileal loop tissues were collected.
Cell Viability
HT29 cells treated with the various agents were incubated with 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) dye for 2 h. The solubilization reagent was added, and absorbance was determined at 570 nm by a spectrophotometer (Model 3550; Bio-Rad, Mississauga, Canada) [18] .
Measurement of Mouse IL-6
Toxin A was previously reported to stimulate the production of interleukin-(IL-6) from target cells [12] . To evaluate whether this occurred in our mouse model of gut inflammation, ileal loops of the above-described mice were homogenized (40 sec) and centrifuged (11,000 rpm, 10 min at 4°C), and supernatants were collected [18] . Mouse IL-6 was measured by ELISA using a commercially available kit (R&D Systems, Minneapolis, MN, USA).
Confocal Scanning Laser Microscopy
For visualization of microtubule structures, colonocytes were exposed for 5 h to control medium, PA, TSA, toxin A alone (1 nM), or toxin A plus PA, and then fixed in 4% paraformaldehyde dissolved in PBS. After being washed with PBS, the cells were incubated with a polyclonal anti-acetylated α-tubulin antibody
